Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal CancerFotios Loupakis, Alfredo Falcone, Chiara Cremolini et al.|New England Journal of Medicine|2014Cited by 1.1k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trialAndrea Sartore‐Bianchi, Salvatore Siena, Livio Trusolino et al.|The Lancet Oncology|2016Cited by 1k
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trialChiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al.|The Lancet Oncology|2020Cited by 322
Assessment of a HER2 scoring system for colorectal cancer: results from a validation studyEmanuele Valtorta, Marcello Gambacorta, Cosimo Martino et al.|Modern Pathology|2015Cited by 317
Nutritional Support in Cancer Patients: A Position Paper from the Italian Society of Medical Oncology (AIOM) and the Italian Society of Artificial Nutrition and Metabolism (SINPE)Riccardo Caccialanza, Vittorina Zagonel, Paolo Pedrazzoli et al.|Journal of Cancer|2015Cited by 144